Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Multidimensional nature of apomorphine SL (IxenseTM) therapy

International Journal of Impotence Research volume 15, pages S13–S15 (2003)Cite this article

Abstract

The aetiology of erectile dysfunction (ED) is multifactorial consisting of psychogenic and organic factors that must be considered in a multidisciplinary manner in order to treat effectively the disorder. New central initiators of erection such as apomorphine SL (IxenseTM) provide a pharmacologically multidimensional approach to the treatment of ED. When used in conjunction with a psychosexual counselling strategy designed to move patients at high risk of failure to high responder groups, it can provide an effective and safe pharmacological therapy for ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Rampin O . Mode of action of a new oral treatment for erectile dysfunction: apomorphine SL. BJU Int 2001; 88(Suppl 3): 22–24.

    Article  CAS  Google Scholar 

  2. McKenna KE . Central control of penile erection. Int J Impot Res 1998; 10(Suppl 1): S25–S34.

    PubMed  Google Scholar 

  3. Mirone VG, Stief CG . Efficacy of apomorphine SL in erectile dysfunction. BJU Int 2001; 88(Suppl 3): 25–29.

    Article  CAS  Google Scholar 

  4. Dula E, Bukofzer S, Perdok R, George M . Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–564.

    Article  CAS  Google Scholar 

  5. Buvat J, Montorsi F . Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int 2001; 88(Suppl 3): 30–35.

    Article  CAS  Google Scholar 

  6. Heaton JP, Dean J, Sleep DJ . Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res 2002; 14: 61–64.

    Article  CAS  Google Scholar 

  7. Andersson KE . Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417–450.

    CAS  Google Scholar 

  8. Johansen LV, Kirkeby HJ, Kiil J . Prevention of erection after penile surgery. A double-blind trial of intracavernous noradrenaline versus placebo. Urol Res 1989; 17: 393–395.

    Article  CAS  Google Scholar 

  9. Andersson KE, Stief C . Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. World J Urol 2001; 19: 9–13.

    Article  CAS  Google Scholar 

  10. Costa P et al. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum. J Urol 1993; 150: 859–863.

    Article  CAS  Google Scholar 

  11. Wagner G, Mulhall J . Pathophysiology and diagnosis of male erectile dysfunction. BJU Int 2001; 88(Suppl 3): 3–10.

    Article  Google Scholar 

  12. Courtois FJ, Goulet MC, Charvier KF, Leriche A . Posttraumatic erectile potential of spinal cord injured men: how physiologic recordings supplement subjective reports. Arch Phys Med Rehabil 1999; 80: 1268–1272.

    Article  CAS  Google Scholar 

  13. Kim SC, Oh MM . Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence. J Urol 1992; 147: 1530–1532.

    Article  CAS  Google Scholar 

  14. Becker AJ et al. Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 2002; 59: 281–286.

    Article  Google Scholar 

  15. Granata A, Bancroft J, Del Rio G . Stress and the erectile response to intracavernosal prostaglandin E1 in men with erectile dysfunction. Psychosom Med 1995; 57: 336–344.

    Article  CAS  Google Scholar 

  16. Aversa A et al. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl 1996; 19: 307–313.

    Article  CAS  Google Scholar 

  17. Beck JG, Barlow DH . The effects of anxiety and attentional focus on sexual responding—I. Physiological patterns in erectile dysfunction. Behav Res Ther 1986; 24: 9–17.

    Article  CAS  Google Scholar 

  18. Hale VE, Strassberg DS . The role of anxiety on sexual arousal. Arch Sex Behav 1990; 19: 569–581.

    Article  CAS  Google Scholar 

  19. Sachs BD . Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. Neurosci Biobehav Rev 2000; 24: 541–560.

    Article  CAS  Google Scholar 

  20. Hendry WF . In: Jardin A (ed). Erectile Dysfunction. Plymbridge Distributors, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hopital Doumergue 5, rue Hoche , Nimes, France

    P Costa

Authors
  1. P Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Costa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa, P. Multidimensional nature of apomorphine SL (IxenseTM) therapy. Int J Impot Res 15 (Suppl 2), S13–S15 (2003). https://doi.org/10.1038/sj.ijir.3900993

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900993

Keywords

Search

Advanced search

Quick links